Biogen Inc. Stock
€160.50
Your prediction
Biogen Inc. Stock
Pros and Cons of Biogen Inc. in the next few years
Pros
Cons
Performance of Biogen Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Biogen Inc. | -0.340% | 2.482% | -0.155% | 19.740% | 7.474% | -39.918% | -29.963% |
| BioMarin Pharmaceutical Inc. | 1.830% | 4.097% | 0.237% | -17.527% | -0.157% | -50.737% | -28.913% |
| AbbVie Inc. | -0.960% | 1.087% | -1.691% | 0.465% | -5.295% | 30.581% | 117.544% |
| Johnson & Johnson | 0.540% | 2.119% | 15.479% | 34.623% | 14.773% | 33.595% | 48.217% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon initial examination, Biogen's financial health appears to be quite stable. The company demonstrates significant total assets backed by a strong shareholder equity. However, it's also essential to dig deeper into the financial landscape of this key player in the pharmaceutical industry to understand its true standing.
Strong Gross Profit: Biogen has consistently reported solid gross profits over the years. This is a positive sign as it indicates effective operations and significant markup on products, a crucial aspect of success within the pharmaceutical industry.
Substantial Assets and Equity: The company boasts noteworthy total assets and shareholder equity. This indicates that Biogen is well-capitalized and has substantial resources at its disposal to facilitate growth and tactical maneuvers in the market.
Comments
News
Why Biogen Stock Surged Almost 9% Higher on Friday
One of the healthier stocks on the market Friday was veteran biotech Biogen (NASDAQ: BIIB). The company unveiled its final set of fundamentals for 2025, and it crushed analyst estimates for both
J.L. Bainbridge Exits Most of Biogen Stake as Biotech Stock Eyes Turnaround
Florida-based wealth advisory J. L. Bainbridge & Co. sold 119,376 shares of Biogen (NASDAQ:BIIB) during the third quarter for an estimated $16.1 million.
In a quarterly disclosure filed with the